Integrative Left Atrial Appendage Technology


Improve AF Outcomes,  

Protect Against LAA Thrombus Formation,

and Post Procedure Patient Management (Heart Failure, AF)

Integrative Left Atrial Appendage Technology


Improve AF Outcomes,  

Protect Against LAA Thrombus Formation,

and Post Procedure Patient Management (Heart Failure, AF)

    Highly Experienced Team

    Randy Werneth

      

    CEO and President

    More than 25 years of experience in both small entrepreneurial and Fortune 500 corporations in the medical device industry.

    Founder of CardioCorX, EPiNova, Acutus Medical, Securus Medical Group, Ablation Frontiers and CryoTherapeutics GmbH with multiple exits.
    Senior leadership positions at Medtronic, Micro Therapeutics, Edwards Lifesciences and Biosensors

    Mr. Werneth holds a B.S. degree in Engineering from Arizona State University (ASU) and a Masters in Science from University of California at Los Angeles (UCLA). 

    He has more than 70 issued U.S. Patents in various medical technology fields.

    J. Christopher Flaherty

      

     Intellectual Property Strategist

    J. Christopher Flaherty has 25 years of experience in the medical device field, with over 150 issued U.S. Patents to his name.

    Christopher founded Insulet Corporation (NASDAQ:PODD) in 2000, and co-founded TransVascular Inc in 1996.

    Christopher has been an invited speaker at the United States Patent and Trademark Office, presenting new technologies. 

    He earned a B.S. in Avionics Engineering from MIT in 1985, where he won the Luis de Florez award for inventiveness.

    Jeffrey Castleberry

      

    Chief Technology Officer 

    A seasoned technical executive with over 30 years of building and leading successful organizations to commercialize complex medical devices including durable equipment, sterile disposables, and implantable products.

    Jeff co-founded Allotrope Medical, ForCast Orthopedic, EndoShape, CardioOptics (Acquired by Olympus), while holding senior position at Plexus Corp., Battelle Memorial Institute and American Cyanamid.

    He earned a B.S. in Mechanical Engineering from Cal Poly State University, San Luis Obisp and an MBA from University of Southern California (Entrepreneurship, R. Buskirk Award Recipient).

    David Zarbatany

      

    Sr. Design Engineering

    David has 25 plus years of experience in the medical device field, accomplished in both Research & Development and Manufacturing Engineering. 

    Leading multiple device development projects from design concept to the first human clinicals. Developing the clinical procedures for completely new Interventional Cardiology devices by learning the anatomy of the cardiovascular system, understanding fluoroscopy and ultrasound images, and with hands-on manipulation of the devices in the pre-clinical model. 

    Mr. Zarbatany earned a B.S. in Mechanical Engineering from Drexel University and a MBA from University of Rhode Island,

    Atrial Fibrillation

    What is Atrial Fibrillation (AFib)

    image10

    AFib is an irregular heartbeat, a rapid heartbeat or a quivering of the upper chambers of the heart. 

    It results from a malfunction in the heart’s electrical system.

    AFib is the most common heart rhythm disorder in the United States, affecting more than three million people. 

    It can lead to heart and valve diseases, sleep apnea and chronic fatigue.

    AFib can also lead to two potentially life-threatening conditions: stroke and congestive heart failure.

    Different Types of AFib

    image11

     Persistent – continuous AFib lasting more than seven days


    Longstanding –  continuous AFib that lasts for one year or longer


    Paroxysmal, or intermittent – episodes of AFib that come and go over the course of seven days or fewer


    Permanent – continuous AFib where a decision has been made not to pursue restoration of sinus rhythm by any means


    Non-valvular – AFib unrelated to valvular disease or prosthetic heart valves

    AFib is progressive. it may start out as  Paroxysmal AFib and later develop Persistent AFib.  Or it may start as  Persistent AFib that later becomes Longstanding persistent AFib.

    Treatments options for AFib

    image12

      1. AFib Diagnosis


    2. Determination of Stroke Risk (CHA2DS2VASc)

    - Aspirin ‒Warfarin vs NOAC vs LAA Occlusion 


    3. RX: ‒Rate Control 

    - Rhythm Control: Antiarrhythmic Drugs vs Ablation


    4. Ablation: 

    - 40-80% need ≥2 procedures 

    - 30-60% long-term success in persistent AF


    No systematic effort to prevent and modify upstream pathways such as sleep apnea, diabetes, obesity, etc. 

    No systematic effort to monitor and treat comorbidities such as heart failure.

    No systematic effort to monitor rhythm for life. 

    AFib Ablation Outcomes

    image13

    Paroxysmal AFib:  

    • Acute procedure success is well above 90%; 
    • Long-term (>12 months) success rates from one procedure lowers to ~70%


    Persistent and long-standing persistent AFib

    • Acute procedure success rates are over 70%;
    • Long-term (>12 months) success rates from one procedure lower to ~43%


    Atrial Fibrillation and the Role of Left Atrial Appendage

    image14

     Left atrial appendage (LAA) is a source of thromboembolism especially in patients with non valvular atrial fibrillation (AF). 


    The relation of AF with LAA mechanical dysfunction has been one of the most popular issues for researchers for a long time.


    Accumulating data reveals that LAA continues to be the one of the most important structure of heart during AF because of its distinctive anatomical, mechanical, and electrophysiological properties.


    Our approach

    Post Procedure Patient Management

     Automated, real-time, rapid and accurate monitoring & recording of Left-Atrial Pressure / Heart Rate / Body Temperature and ECGs, etc.

     

    Next Gen Technology

     Improve AF Treatment

    --> LAA Electrical Isolation

     

    Prevent Thrombus Forming

    --> Complete LAA Filling


    Manage HF/AF Patient 

    --> Real-time Bio data recording

    CardioCorX mission & Vision

    image15

    Mission

      

    CardioCorX is committed to transforming the lives of millions of patients effected by atrial fibrillation and heart failure by providing Physicians with a unique-to-market integrative platform product that electrically isolate the Left-Atrial Appendage(LAA) eliminating the arrhythmogenic sources coming from the LAA, preventing blood clots/thrombus from forming in the LAA and managing the patient after the procedure using the patients own left atrial pressure (LAP), heart rate (HR), body temperature (BT) and electrocardiograms (ECG).

    Vision

      

    To build the most valuable structural heart / electrophysiology company in the left-atrial appendage market. 

    1. Valued first by the patients whose lives we significantly improved.  
    2. Valued by physicians and caregivers as the most innovative and responsive company in our market globally.  
    3. Valued by employees as a company that’s enabled the best professional experiences of there lives.  
    4. Valued by shareholders as a company that consistently produces market leading returns  

    Features and Benefits

    Next Generation Left Atrial Appendage Device

    Left Atrial Appendage Technology / Device to Improve atrial fibrillation

    device not approved for commercial use

    Contact Us

    CardioCorX

    We love visitors, so feel free to visit during normal business hours.

    Address

    535 Stevens Ave. West, Solana Beach, CA 92075